This phase 1 trial is assessing the safety, tolerability and effectiveness of a novel bacterial therapy (bacTRL-IL-12) to treat advanced solid tumours that have not responded to treatment.
This trial is treating patients with advanced solid tumours.
This is a systemic therapy.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multi-centre, Open-label, Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours
Iqvia Pty Ltd
Patients eligible to participate in this trial will partake in a screening period of 14 days, treatment and observation for 22 days and a safety follow-up period between Day 28 to Day 31. Patients will receive a single dose of intravenously administered bacTRL-IL-12.
Recruiting Hospitals Read More